Baxter International Reports Q3 2026 Growth and Raises Full-Year Guidance
Baxter International (BAX) reported third-quarter revenue of $3 billion, representing a 5% increase on both a reported and organic basis. While adjusted earnings per share fell 16% to $0.58 due to a higher effective tax rate, the company raised its full-year 2026 organic sales guidance to a range of 3% to 4%. Strong performance in Advanced Surgery (up 12%) and Drug Compounding (up 9%) helped offset declines in the injectables segment caused by manufacturing challenges at the Round Lake facility. The company is actively focusing on deleveraging, having retired $864 million in debt through a recent cash tender offer. Management aims to reach a net leverage target of approximately 3x by the end of 2026. Despite margin pressures from sales mix and pricing headwinds, Baxter's operational improvements and cost-reduction initiatives have led to an upward revision of its full-year adjusted EPS guidance.
Tickers: $BAX
Topics: Debt Reduction EPS Guidance Free Cash Flow Revenue Growth Segment Performance